Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Carregando...
Citações na Scopus
39
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
REICH, Kristian
LEONARDI, Craig
LEBWOHL, Mark
KERDEL, Francisco
OKUBO, Yukari
GOLDBLUM, Orin
DENNEHY, Ellen B.
KERR, Lisa
SOFEN, Howard
Citação
JOURNAL OF DERMATOLOGICAL TREATMENT, v.28, n.4, p.282-287, 2017
Resumo
Background: Scalp is a frequently affected and difficult-to-treat area in psoriasis patients.Objective: We assessed the efficacy of ixekizumab in the treatment of patients with scalp psoriasis over 60 weeks using the Psoriasis Scalp Severity Index (PSSI).Methods: In three Phase 3, multicenter, double-blind, placebo-controlled trials, patients with moderate-to-severe psoriasis in UNCOVER-1 (N=1296), UNCOVER-2 (N=1224) and UNCOVER-3 (N=1346) were randomized to subcutaneous 80mg ixekizumab every two weeks (Q2W) or every four weeks (Q4W) after a 160mg starting dose, or placebo through Week 12. Additional UNCOVER-2 and UNCOVER-3 cohorts were randomized to 50mg bi-weekly etanercept through Week 12. Patients entering the open-label long-term extension (LTE) (UNCOVER-3) received ixekizumab Q4W; UNCOVER-1 and UNCOVER-2 included a blinded maintenance period in which static physician global assessment (sPGA) 0/1 responders were re-randomized to placebo, ixekizumab Q4W, or 80mg ixekizumab every 12 weeks (Q12W) through Week 60.Results: In patients with moderate-to-severe psoriasis with baseline scalp involvement, PSSI 90 and 100 were achieved at Week 12 in higher percentages of patients treated with ixekizumab Q2W (81.7% and 74.6%) or ixekizumab Q4W (75.6% and 68.9%) compared with patients treated with placebo (7.6% and 6.7%; p<.001 each ixekizumab arm versus placebo) or etanercept (55.5% and 48.1%; p<.001 each ixekizumab arm versus etanercept). These outcomes were maintained through Week 60 of the maintenance (UNCOVER-1 and UNCOVER-2) and LTE (UNCOVER-3) period in patients who continued on ixekizumab Q4W.Conclusion: Ixekizumab was efficacious in treating scalp psoriasis in patients with moderate-to-severe psoriasis, with most patients achieving complete or near-complete resolution of scalp psoriasis and maintaining this response over 60 weeks.
Palavras-chave
Psoriasis, scalp, clinical trial, UNCOVER, ixekizumab, interleukin-17A
Referências
- Bagel J, 2012, J AM ACAD DERMATOL, V67, P86, DOI 10.1016/j.jaad.2011.07.034
- Chan CS, 2009, J AM ACAD DERMATOL, V60, P962, DOI 10.1016/j.jaad.2008.11.890
- Crowley J, 2010, J DRUGS DERMATOL, V9, P912
- Frez MLF, 2014, J DERMATOL TREAT, V25, P38, DOI 10.3109/09546634.2012.742176
- Gordon KB, 2016, NEW ENGL J MED, V375, P345, DOI 10.1056/NEJMoa1512711
- Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8
- Krell J, 2008, J AM ACAD DERMATOL, V58, P609, DOI 10.1016/j.jaad.2007.12.031
- Langley RG, 2015, J EUR ACAD DERMATOL, V29, P1763, DOI 10.1111/jdv.12996
- Papp K, 2007, J EUR ACAD DERMATOL, V21, P1151, DOI 10.1111/j.1468-3083.2007.02424.x
- Puig L, 2014, J EUR ACAD DERMATOL, V28, P1633, DOI 10.1111/jdv.12238
- Takeshita J, 2014, J AM ACAD DERMATOL, V71, P633, DOI 10.1016/j.jaad.2014.05.001
- Thaci D, 2015, J EUR ACAD DERMATOL, V29, P353, DOI 10.1111/jdv.12553
- Torii H, 2012, J DERMATOL, V39, P253, DOI 10.1111/j.1346-8138.2011.01459.x
- van de Kerkhof PCM, 1998, DERMATOLOGY, V197, P326, DOI 10.1159/000018026
- Viswanathan HN, 2015, J DERMATOL TREAT, V26, P235, DOI 10.3109/09546634.2014.943687
- Wozel G, 2008, CLIN DERMATOL, V26, P448, DOI 10.1016/j.clindermatol.2007.10.026